Shang Yingli, Liu Yong, Du Lei, Wang Youliang, Cheng Xuan, Xiao Weiming, Wang Xiaohui, Jin Haijing, Yang Xiao, Liu Shusen, Chen Quan
Laboratory of Apoptosis and Cancer Biology, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Hepatology. 2009 Oct;50(4):1204-16. doi: 10.1002/hep.23121.
Normal hepatocytes do not express endogenous uncoupling protein 2 (UCP2) in adult liver, although Kupffer cells do, and it is strikingly induced in hepatocytes in steatotic liver and obese conditions. However, the direct link of UCP2 with the pathogenic development of liver diseases and liver injury remains elusive. Here we report that targeted expression of UCP2 to mouse liver increases susceptibility to acute liver injury induced by lipopolysaccharide (LPS) and galactosamine (GalN). UCP2 appears to enhance proton leak, leading to mild uncoupling in a guanosine diphosphate-repressible manner. Indeed, mitochondria from the genetically manipulated mouse liver have increased state 4 respiration, lower respiratory control ratio, and reduced adenosine triphosphate (ATP) levels, which altered mitochondrial physiology. To address the underlying mechanism of how UCP2 and the reduced energy coupling efficiency enhance cell death in mouse liver, we show that the reduced ATP levels lead to activation of 5'AMP-activated protein kinase (AMPK) and its downstream effector, c-Jun N-terminal kinase; thus, the increased sensitivity toward LPS/GalN-induces apoptosis. Importantly, we show that inhibition of UCP2 activity by its pharmacological inhibitor genipin prevents LPS/GalN-induced ATP reduction, AMPK activation, and apoptosis. Also, inhibition of ATP production by oligomycin promotes LPS/GalN-induced cell death both in vivo and in vitro.
Our results clearly show that targeted expression of UCP2 in liver may result in compromised mitochondrial physiology that contributes to enhanced cell death and suggests a potential role of UCP2 in the development of liver diseases.
正常肝细胞在成年肝脏中不表达内源性解偶联蛋白2(UCP2),尽管库普弗细胞会表达,并且在脂肪变性肝脏和肥胖状态下的肝细胞中它会显著被诱导。然而,UCP2与肝脏疾病和肝损伤致病发展的直接联系仍不清楚。在此我们报告,将UCP2靶向表达于小鼠肝脏会增加其对脂多糖(LPS)和半乳糖胺(GalN)诱导的急性肝损伤的易感性。UCP2似乎增强了质子泄漏,导致以鸟苷二磷酸可抑制的方式出现轻度解偶联。实际上,来自基因操作小鼠肝脏的线粒体状态4呼吸增加、呼吸控制率降低以及三磷酸腺苷(ATP)水平降低,这改变了线粒体生理学。为了探究UCP2和能量偶联效率降低如何增强小鼠肝脏细胞死亡的潜在机制,我们发现ATP水平降低会导致5'单磷酸腺苷激活的蛋白激酶(AMPK)及其下游效应物c-Jun氨基末端激酶激活;因此,对LPS/GalN诱导的细胞凋亡的敏感性增加。重要的是,我们表明其药理学抑制剂京尼平对UCP2活性的抑制可防止LPS/GalN诱导的ATP降低、AMPK激活和细胞凋亡。此外,寡霉素对ATP生成的抑制在体内和体外均促进LPS/GalN诱导的细胞死亡。
我们的结果清楚地表明,UCP2在肝脏中的靶向表达可能导致线粒体生理学受损,这有助于增强细胞死亡,并提示UCP2在肝脏疾病发展中具有潜在作用。